JP2022516086A - 神経網膜疾患の治療および／または予防における治療活性物質として使用するための化合物 - Google Patents
神経網膜疾患の治療および／または予防における治療活性物質として使用するための化合物 Download PDFInfo
- Publication number
- JP2022516086A JP2022516086A JP2021537220A JP2021537220A JP2022516086A JP 2022516086 A JP2022516086 A JP 2022516086A JP 2021537220 A JP2021537220 A JP 2021537220A JP 2021537220 A JP2021537220 A JP 2021537220A JP 2022516086 A JP2022516086 A JP 2022516086A
- Authority
- JP
- Japan
- Prior art keywords
- group
- retinal
- compound
- atom
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *C(C=CC(C1)NC(Cc2c(*)c(*)c(*)c(*)c2*)=O)=C1I Chemical compound *C(C=CC(C1)NC(Cc2c(*)c(*)c(*)c(*)c2*)=O)=C1I 0.000 description 4
- JZZFRTXYKLGFCF-UHFFFAOYSA-N COc(cc(cc1)NC(Cc2ccccc2)=O)c1-c1ccncc1 Chemical compound COc(cc(cc1)NC(Cc2ccccc2)=O)c1-c1ccncc1 JZZFRTXYKLGFCF-UHFFFAOYSA-N 0.000 description 1
- DSQPJPCADQCPRC-UHFFFAOYSA-N COc(cc(cc1)NC(Cc2ccccc2Cl)=O)c1-c1ccncc1 Chemical compound COc(cc(cc1)NC(Cc2ccccc2Cl)=O)c1-c1ccncc1 DSQPJPCADQCPRC-UHFFFAOYSA-N 0.000 description 1
- VOEOOXPPXZHFQM-UHFFFAOYSA-N COc1c(CC(Nc(cc2)cc(Cl)c2-c2cnc[o]2)=O)cccc1 Chemical compound COc1c(CC(Nc(cc2)cc(Cl)c2-c2cnc[o]2)=O)cccc1 VOEOOXPPXZHFQM-UHFFFAOYSA-N 0.000 description 1
- QXDILVUCFQVKTM-UHFFFAOYSA-N COc1cc(CC(Nc(cc2)ccc2-c2ccncc2)=O)ccc1 Chemical compound COc1cc(CC(Nc(cc2)ccc2-c2ccncc2)=O)ccc1 QXDILVUCFQVKTM-UHFFFAOYSA-N 0.000 description 1
- BBNNLJMGPASZPD-UHFFFAOYSA-N Cc(cc1)ccc1S(CC#N)(=O)=O Chemical compound Cc(cc1)ccc1S(CC#N)(=O)=O BBNNLJMGPASZPD-UHFFFAOYSA-N 0.000 description 1
- YBEAMOBHNFDQMM-UHFFFAOYSA-N Nc1cnc[o]1 Chemical compound Nc1cnc[o]1 YBEAMOBHNFDQMM-UHFFFAOYSA-N 0.000 description 1
- LWOMDEOMDYBFGJ-UHFFFAOYSA-N O=C(Cc(cc1)ccc1Cl)Nc(cc1)cc(Cl)c1-c1cnc[o]1 Chemical compound O=C(Cc(cc1)ccc1Cl)Nc(cc1)cc(Cl)c1-c1cnc[o]1 LWOMDEOMDYBFGJ-UHFFFAOYSA-N 0.000 description 1
- CQJDPVVGJCSKSV-UHFFFAOYSA-N O=C(Cc(ccc(F)c1)c1F)Nc(cc1)cc(Cl)c1-c1cnc[o]1 Chemical compound O=C(Cc(ccc(F)c1)c1F)Nc(cc1)cc(Cl)c1-c1cnc[o]1 CQJDPVVGJCSKSV-UHFFFAOYSA-N 0.000 description 1
- OVFPQBROLOGEMT-UHFFFAOYSA-N O=C(Cc(cccc1)c1Cl)Nc(cc1)cc(Cl)c1-c1cnc[o]1 Chemical compound O=C(Cc(cccc1)c1Cl)Nc(cc1)cc(Cl)c1-c1cnc[o]1 OVFPQBROLOGEMT-UHFFFAOYSA-N 0.000 description 1
- PHLMJLIUEODRIV-UHFFFAOYSA-N O=C(Cc(cccc1)c1Cl)Nc(cc1)cc(F)c1-c1cnc[o]1 Chemical compound O=C(Cc(cccc1)c1Cl)Nc(cc1)cc(F)c1-c1cnc[o]1 PHLMJLIUEODRIV-UHFFFAOYSA-N 0.000 description 1
- XYVMTOOLDHJRMH-UHFFFAOYSA-N O=C(Cc(cccc1)c1OC(F)F)Nc(cc1)cc(F)c1-c1cnc[o]1 Chemical compound O=C(Cc(cccc1)c1OC(F)F)Nc(cc1)cc(F)c1-c1cnc[o]1 XYVMTOOLDHJRMH-UHFFFAOYSA-N 0.000 description 1
- NYJDZFHYWCGKOI-UHFFFAOYSA-N O=C(Cc1cc(C(F)(F)F)ccc1)Nc(cc1)cc(Cl)c1-c1cnc[o]1 Chemical compound O=C(Cc1cc(C(F)(F)F)ccc1)Nc(cc1)cc(Cl)c1-c1cnc[o]1 NYJDZFHYWCGKOI-UHFFFAOYSA-N 0.000 description 1
- NIPNGJSDFBOBES-UHFFFAOYSA-N O=C(Cc1ccccc1OC(F)F)Nc(cc1)cc(Cl)c1-c1cnc[o]1 Chemical compound O=C(Cc1ccccc1OC(F)F)Nc(cc1)cc(Cl)c1-c1cnc[o]1 NIPNGJSDFBOBES-UHFFFAOYSA-N 0.000 description 1
- LXRXBYOUAYVTHT-UHFFFAOYSA-N [O-][N+](c(cc1)cc(F)c1-c1cnc[o]1)=O Chemical compound [O-][N+](c(cc1)cc(F)c1-c1cnc[o]1)=O LXRXBYOUAYVTHT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/235,543 | 2018-12-28 | ||
| US16/235,543 US10752593B2 (en) | 2018-12-28 | 2018-12-28 | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| PCT/US2019/068759 WO2020140043A1 (en) | 2018-12-28 | 2019-12-27 | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516086A true JP2022516086A (ja) | 2022-02-24 |
| JP2022516086A5 JP2022516086A5 (https=) | 2022-11-30 |
Family
ID=69188012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537220A Withdrawn JP2022516086A (ja) | 2018-12-28 | 2019-12-27 | 神経網膜疾患の治療および／または予防における治療活性物質として使用するための化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10752593B2 (https=) |
| EP (1) | EP3902606A1 (https=) |
| JP (1) | JP2022516086A (https=) |
| KR (1) | KR20210110849A (https=) |
| CN (1) | CN113301958A (https=) |
| AU (1) | AU2019414950A1 (https=) |
| BR (1) | BR112021011599A2 (https=) |
| CA (1) | CA3125278A1 (https=) |
| CL (1) | CL2021001725A1 (https=) |
| EA (1) | EA202191057A1 (https=) |
| IL (1) | IL284298A (https=) |
| MX (1) | MX2021007813A (https=) |
| PH (1) | PH12021551092A1 (https=) |
| SG (1) | SG11202104958UA (https=) |
| WO (1) | WO2020140043A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010758A1 (en) | 1996-09-13 | 1998-03-19 | The Regents Of The University Of California | Methods for treatment of retinal diseases |
| CA2216439A1 (en) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
| WO2001039792A2 (en) | 1999-12-03 | 2001-06-07 | Alcon Universal Ltd. | The use of caspase 9 inhibitors to treat ocular neural pathology |
| AU2008335709A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| US9018202B2 (en) | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| US20130046003A1 (en) | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| WO2014079850A1 (en) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
| DE102013110714A1 (de) | 2013-09-27 | 2015-04-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung |
| BR112017009584A2 (pt) | 2014-11-07 | 2017-12-26 | Nacuity Pharmaceuticals Inc | tratamento de retinite pigmentosa com n-acetilcisteína amida |
-
2018
- 2018-12-28 US US16/235,543 patent/US10752593B2/en not_active Expired - Fee Related
-
2019
- 2019-12-27 MX MX2021007813A patent/MX2021007813A/es unknown
- 2019-12-27 EA EA202191057A patent/EA202191057A1/ru unknown
- 2019-12-27 WO PCT/US2019/068759 patent/WO2020140043A1/en not_active Ceased
- 2019-12-27 CA CA3125278A patent/CA3125278A1/en active Pending
- 2019-12-27 AU AU2019414950A patent/AU2019414950A1/en not_active Abandoned
- 2019-12-27 EP EP19842557.1A patent/EP3902606A1/en not_active Withdrawn
- 2019-12-27 KR KR1020217023914A patent/KR20210110849A/ko not_active Ceased
- 2019-12-27 BR BR112021011599-4A patent/BR112021011599A2/pt not_active Application Discontinuation
- 2019-12-27 CN CN201980085675.1A patent/CN113301958A/zh active Pending
- 2019-12-27 JP JP2021537220A patent/JP2022516086A/ja not_active Withdrawn
- 2019-12-27 SG SG11202104958UA patent/SG11202104958UA/en unknown
-
2021
- 2021-05-11 PH PH12021551092A patent/PH12021551092A1/en unknown
- 2021-06-22 IL IL284298A patent/IL284298A/en unknown
- 2021-06-25 CL CL2021001725A patent/CL2021001725A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3125278A1 (en) | 2020-07-02 |
| IL284298A (en) | 2021-08-31 |
| EA202191057A1 (ru) | 2021-10-07 |
| KR20210110849A (ko) | 2021-09-09 |
| SG11202104958UA (en) | 2021-07-29 |
| AU2019414950A1 (en) | 2021-06-03 |
| WO2020140043A1 (en) | 2020-07-02 |
| EP3902606A1 (en) | 2021-11-03 |
| MX2021007813A (es) | 2021-10-01 |
| US20200207719A1 (en) | 2020-07-02 |
| BR112021011599A2 (pt) | 2021-08-31 |
| CL2021001725A1 (es) | 2021-12-17 |
| PH12021551092A1 (en) | 2021-12-06 |
| US10752593B2 (en) | 2020-08-25 |
| CN113301958A (zh) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI532480B (zh) | 以斑馬魚模組進行藥物篩選之方法及篩選所得藥物 | |
| US11844755B2 (en) | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium | |
| KR102876332B1 (ko) | 신경망막 질환의 치료 및/또는 예방에 치료적 활성 물질로서 사용하기 위한 화합물 | |
| JP2022516086A (ja) | 神経網膜疾患の治療および／または予防における治療活性物質として使用するための化合物 | |
| US20220089547A1 (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | |
| HK40050821A (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | |
| HK40049629A (en) | N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | |
| EA042985B1 (ru) | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний | |
| CN115916192B (zh) | 新化合物及其作为治疗活性物质在治疗和/或预防涉及视网膜色素上皮的疾病中的应用 | |
| EA050984B1 (ru) | Новые соединения и их применение в качестве терапевтически активных веществ для лечения и/или предотвращения заболеваний, затрагивающих пигментный эпителий сетчатки | |
| HK40049629B (zh) | 作为用於治疗神经视网膜疾病的视网膜前体细胞的生产的刺激剂的n-(4-(恶唑-5-基)苯基)色满-3-甲酰胺衍生物及相关化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221118 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221118 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20231101 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231109 |